# Fibrates

Drug · id `cardio:fibrates` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Fibric acid derivatives; Fibric acids

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

Fibrates are cholesterol-lowering medicines that lower triglycerides. MedlinePlus says they do this in several ways, including by reducing the triglycerides the liver makes, and that they may also raise HDL cholesterol and lower LDL cholesterol a little. A US label for one fenofibrate product (Antara) calls it a PPAR alpha agonist. This is the class page; one member substance, fenofibrate, has its own page.

## Technical summary

Class page. MeSH descriptor D058607 (Fibric Acids) is a broad match: its scope note describes compounds that share, or vary, the fibric acid structure, a chemical group rather than the medicine class; Fibric Acid Derivatives is a MeSH entry term (read 2026-11-18, hash only). RxClass gives fenofibrate and gemfibrozil the chemical class Fibric Acids and the pharmacologic class Peroxisome Proliferator-activated Receptor alpha Agonist (from US drug labels, read 2026-11-18). The Antara label read (Lupin Pharmaceuticals, NDA021695, effective 2025-10-01 in openFDA) says fenofibric acid, the active moiety, acts by activating the PPAR alpha receptor. The MedlinePlus cholesterol medicines page adds that taking fibrates together with another class of cholesterol medicine might raise the risk of side effects. No brand-name gemfibrozil label was returned by openFDA, and one member substance, fenofibrate, is recorded; gemfibrozil has no page. No trial result and no dose is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- MedlinePlus: fibrates lower triglycerides: High triglycerides (`cardio:hypertriglyceridemia`)
- MedlinePlus: taking fibrates with statins might raise the risk of side effects: Statins (`cardio:statins`)
- Has subtype: Fenofibrate (`cardio:fenofibrate`)

## Provenance

Content hash: 2cdecb34977a98c1f1085208e309357afc597159bc63d2837a18e00544045482
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
